.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AD12_ProteinC.ProteinC .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AD12_ProteinC.ProteinC| name: | ProteinC |
| ATC code: | B01AD12 | route: | intravenous |
| n-compartments | 2 |
Protein C is a vitamin K-dependent glycoprotein in plasma that, when activated, exhibits anticoagulant properties by proteolytic inactivation of Factors Va and VIIIa. It is used as a replacement therapy in individuals with hereditary protein C deficiency to prevent and treat venous thrombosis and purpura fulminans. Protein C concentrates are approved and were mainly used for congenital deficiency, especially in newborns and children, but are rarely used today due to the rarity of the indication.
Pharmacokinetic parameters reported for human plasma-derived protein C concentrate in healthy adult volunteers and patients with hereditary protein C deficiency.
Upert, G, et al., & Ermert, P (2021). Emerging peptide antibiotics with therapeutic potential. Medicine in drug discovery 9 100078–None. DOI:10.1016/j.medidd.2020.100078 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33398258
Li, Z, et al., & Taylor, A (2025). Evaluation of pharmacokinetics of intravenous protein C concentrate in protein C deficiency: implications for treatment initiation and maintenance. Research and practice in thrombosis and haemostasis 9(3) 102859–None. DOI:10.1016/j.rpth.2025.102859 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40492255
Troisi, C, et al., & Pea, F (2024). Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia. Clinical pharmacokinetics 63(11) 1573–1583. DOI:10.1007/s40262-024-01436-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39455501